GleamWall
中文EN

BTCY BIOTRICITY INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1630113 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.7%
TTM net income YoY38.0%
TTM EPS YoY-4.9%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin9.7%
Net margin-16.7%
FCF margin—
EBITDA margin9.7%

Returns

ROE—
ROA-45.2%
ROIC (approx.)—
Asset turnover2.71x

Leverage & solvency

Liabilities / assets662.7%
Debt / equity—
Current ratio0.15x
Interest coverage0.49x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-41.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue$16.00M$13.79M
Cost of revenue$3.05M$3.23M
Gross profit$12.95M$10.56M
R&D expense$2.76M$2.16M
SG&A expense$8.49M$10.86M
Operating income$1.69M-$2.45M
Interest expense$3.36M$3.26M
Pretax income-$2.40M-$8.42M
Net income-$2.40M-$8.42M
EBITDA$1.70M-$2.44M
EPS (basic)-0.12-0.56
EPS (diluted)-0.12-0.56
Weighted avg. shares (diluted)27.30M21.52M
Balance sheet
Cash & equivalents$149,789$365,145
Receivables$2.93M$1.66M
Inventory$1.34M$1.56M
Current assets$5.86M$4.64M
PP&E, net$3,646$9,599
Total assets$6.45M$5.64M
Current liabilities$37.14M$20.64M
Total liabilities$39.41M$35.66M
Shareholders' equity-$34.68M-$32.01M
Shares outstanding28.60M26.08M
Cash flow statement
Operating cash flow-$718,955-$2.38M
Financing cash flow$557,736$1.93M
Depreciation & amortization$5,953$5,953
Stock-based compensation$25,632$1.46M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.